News for Healthier Living

Beyond High-Dose IL-2: A novelTIL Expansion Platform Improves Safety and Efficacyof TIL Therapyina Preclinical Study

Adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) has emerged as a powerful immunotherapy for solid tumors, yet its broader application is constrained by reliance on high-dose interleukin-2 (IL-2), a cytokine that activates T cells but also drives T-cell exhaustion and causes severe toxicity.

July 3, 2026


July 17 2026

July 16 2026

July 15 2026

July 14 2026

July 13 2026

July 12 2026

July 10 2026

July 9 2026

July 8 2026

July 7 2026

July 6 2026

July 3 2026